SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Medicenna Therapeutics Corp. (MDNA) trades at a trailing P/E of 6.6. Trailing earnings yield is 15.22%.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (6.6); earnings yield beats bond yields (15.22%).
- Trailing Earnings Yield 15.22% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MDNA
Valuation Multiples
P/E (TTM)6.6
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.02
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield15.22%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-0.05 |
$0.00 |
$-766.00 |
- |
| 2015 |
$-0.05 |
$0.00 |
$-833.00 |
- |
| 2016 |
$-0.08 |
$0.00 |
$-1.33M |
- |
| 2017 |
$-0.45 |
$0.00 |
$-7.63M |
- |
| 2018 |
$-0.31 |
$0.00 |
$-7.47M |
- |
| 2019 |
$-0.18 |
$0.00 |
$-4.71M |
- |
| 2020 |
$-0.26 |
$0.00 |
$-8.31M |
- |
| 2021 |
$-0.35 |
$0.00 |
$-17.18M |
- |
| 2022 |
$-0.42 |
$0.00 |
$-22.65M |
- |
| 2023 |
$0.02 |
$0.00 |
$1.55M |
- |
